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Abstract 
A panel of national experts was convened by the Brazilian Infectious Diseases Society in order to organize the national 
recommendations for the management of zika virus infection. The focus of this document is the diagnosis, both clini-
cal and laboratorial, and appropriate treatment of the diverse manifestations of this infection, ranging from acute mild 
disease to Guillain-Barré syndrome and also microcephaly and congenital malformations.
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Background
The Zika virus is an arbovirus of the genus Flavivirus, in 
the family Flaviviridae, which was first identified in 1947, 
in the Zika Forest in Uganda during a monitoring pro-
gram on wild yellow fever [1–4]. It is related to other fla-
viviruses, including the viruses that cause dengue, yellow 
fever and West Nile fever.
Outbreaks of the disease were first notified in the 
Pacific region in 2007 and 2013, respectively in the Yap 
islands and in French Polynesia, and then in the Ameri-
cas (Brazil and Colombia) and in Africa (Cape Verde) in 
2015 [2, 3, 5, 6]. Rapid geographical expansion has been 
observed since then, with 40 countries in the Americas 
reporting autochthonous transmission as sporadic cases 
or outbreaks. It is also important to mention the growing 
number of countries on other continents that have been 
notifying occurrences of imported cases of Zika virus 
infection, thus demonstrating its great potential for dis-
semination on a worldwide scale [7].
Through occurrences of Zika outbreaks, the central 
nervous system and autoimmune complications that 
were previously reported in French Polynesia have also 
come to be observed in the Americas.
Zika infection during pregnancy has been correlated 
with congenital microcephaly, fetal malformations and 
fetal losses. This led the Brazilian Ministry of Health to 
declare a state of public health emergency of national 
importance in November 2015, after observation of 
changes to the epidemiological pattern of occurrences of 
microcephaly in Pernambuco and other states in north-
eastern Brazil [8, 9].
In the light of the significant increase in the incidence 
of neurological syndromes and cases of microcephaly 
that were potentially related to the Zika virus, the World 
Health Organization (WHO) declared an international 
public health state of emergency in February 2016. To 
put the importance of this event into context, this was 
the fourth time that WHO has ever declared a worldwide 
state of emergency in relation to a viral epidemic. The 
previous decisions were made in relation to H1N1 (2009), 
poliomyelitis (2014) and Ebola (2014).
On February 18, 2016, the Brazilian Ministry of Health 
issued an ordinance that made it compulsory to notify 
suspected cases of Zika throughout the country. This dis-
ease has thus been added to other arboviruses, such as 
dengue, yellow fever, West Nile fever and chikungunya, 
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which were already on the national list of diseases with 
compulsory notification [10].
Epidemiology
Geographical distribution
In humans, the Zika virus was first identified in Uganda 
and Tanzania, in 1952 [11]. Between 1952 and 1981, a 
variety of serological evidence regarding infection by this 
virus was reported from countries in Africa and some 
parts of Asia [4].
The first epidemic outside of Africa and Asia occurred 
in 2007, in the Yap islands of Micronesia. It was esti-
mated that more than 70 % of the population over the age 
of 3  years became infected [2]. Another large outbreak 
of Zika fever occurred concomitantly with a dengue epi-
demic (serotypes 1 and 3) in French Polynesia in 2013–
2014, affecting around 32,000 people [3].
In 2014, cases of Zika virus infection were reported 
on Easter Island, which is Chilean territory [12]. In May 
2015, some months after reports of increased incidence 
of exanthematous febrile disease in states of northeast-
ern Brazil, which until then were of unidentified cause, 
presence of Zika virus circulation was confirmed in this 
country. This was initially confirmed in Bahia on April 
29, 2015, from analysis on samples from patients with an 
exanthematous condition in Camaçari, Bahia, and sub-
sequently in Rio Grande do Norte on May 9, 2015, with 
identification of the Asian genotype [13, 14]. Also in 
May, cases in Sumaré and Campinas (São Paulo), Maceió 
(Alagoas) and Belém (Pará) were confirmed through lab-
oratory tests. Since then, rapid expansion of the areas of 
circulation and autochthonous transmission of the virus 
has been observed, notably in states of the northeastern 
region of Brazil. It is estimated that more than one mil-
lion Brazilians became infected with the Zika virus in 
2015, thus reflecting the capacity of the virus to cause 
large-scale outbreaks in places where the biological vec-
tor is present.
Worldwide, the virus is now circulating in 65 countries 
and territories, mostly in the Americas [15].
Transmission methods
Zika is transmitted primarily through the bites of 
infected mosquitos of the genus Aedes, especially Aedes 
aegypti and Aedes albopictus [16].
In humans, except for pregnant women, the period of 
viremia is short and it is most frequently identified by the 
5th day after the symptoms start. The RNA of the Zika 
virus has been identified in blood as early as on the 1st 
day, and also only up to 11 days after the disease begins. 
Prolonged Zika virus RNA was detected in serum of four 
symptomatic pregnant women in up to 46  days after 
symptoms onset and in one asymptomatic pregnant 
woman 53 days after infection [17]. In pregnant women 
Zika virus RNA has been detected for up to 10  weeks 
after infection [18].
In addition to vector transmission, other forms of 
transmission that so far are just theoretical or anecdotal 
have started to receive greater attention. The RNA of the 
Zika virus has now been detected in blood, urine, semen, 
saliva, female genital tract secretions, cerebrospinal fluid, 
amniotic fluid and breastmilk [16, 19– 25].
After two likely cases of transmission through blood 
transfusion in Campinas, São Paulo, were identified, 
there has been much discussion about the importance of 
this transmission route [26].
Reports of detection of Zika in urine through PCR up 
to 20  days after the start of symptoms, in a study con-
ducted in French Polynesia, even without any confirma-
tion of infectiveness, have given rise to discussion on the 
need for better comprehension of the importance of this 
biological material as an infecting agent [21].
Zika has been detected in semen for periods of up to 
10 weeks after recovery from the symptoms of the infec-
tion, and likely cases of sexual transmission from men 
to women have been described. Eleven countries have 
reported evidence of person-to-person transmission of 
Zika virus, probably via a sexual route [15].
Tests conducted on the amniotic fluid of pregnant 
women with possible Zika virus infection whose fetuses 
had been diagnosed as presenting microcephaly have 
been found to be positive for the Zika virus [27]. This 
shows that the virus has the capacity to cross the placen-
tal barrier and, increasingly evidently, that it causes fetal 
malformations.
Presence of the virus has already been shown through 
detection of viral RNA in the breastmilk of moth-
ers with conditions of acute infection. It is expected 
a higher viral load of Zika virus in maternal milk for 
women infected near delivery, and not expected to 
occur with first trimester infections. In New Caledo-
nia it has been reported the presence of infectious Zika 
virus particles in breast milk with substantial viral 
loads [28]. However, since there have not been any con-
firmed cases of transmission through breastfeeding, 
the guidance continues to be that breastfeeding should 
be maintained, given that the benefits of breastfeed-
ing override the risks of virus transmission through 
breastmilk, which remains unproven [22]. In the light 
of present knowledge, identification of the virus in 
urine, breastmilk, saliva and semen is potentially useful 
in diagnosing the disease, but the possibility of impor-
tance of such findings for virus transmission to other 
people cannot be confirmed.
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Clinical manifestations
Signs and symptoms
It has been estimated that clinical manifestations occur 
in around 20 % of infected individuals. Hence, asympto-
matic infection occurs more frequently. These estimates 
have been based on a single study that was conducted 
through a household serological survey involving sero-
logical tests for Zika (IgM) [2].
The duration of incubation in humans is unknown, but 
it has been estimated to be 2–14 days after the bite of the 
vector mosquito [29].
The clinical condition typically includes a maculo-
papular rash, frequently accompanied by pruritus, low 
fever (37.8–38.5  °C), arthralgia (especially in the joints 
of the hands and feet) and non-purulent conjunctivitis. 
Other manifestations that have commonly been reported 
include myalgia, headache, retro-orbital pain and asthe-
nia. Periarticular edema, oral lymphadenopathy, oral 
ulcers, abdominal pain, nausea and diarrhea may also 
occur [2, 13, 14].
In most patients, the symptoms are usually mild and pre-
sent spontaneous resolution after 2–7  days. However, in 
some patients, arthralgia may persist for around 1 month.
•  So far, the length of the immunity conferred through 
natural infection with the Zika virus remains unknown.
Brazilian ministry of health’s definition of suspected zika 
cases
•  Suspected case: “Patients who present pruriginous 
maculopapular exanthema accompanied by two or 
more of the following signs and symptoms:
 – Fever
  – Conjunctival hyperemia without secretion and pru-
ritus
  – Polyarthralgia
 – Periarticular edema”
Brazilian ministry of health’s definition of confirmed 
zika cases
•  Confirmed case: “Suspected case in which one of the 
following tests is positive or shows a specific reaction 
for a diagnosis of Zika:
 – Isolation of the virus
  – Detection of viral RNA through the reverse tran-
scriptase reaction (RT-PCR)
  – IgM serological test (in populations presenting 
co-circulation of the dengue virus, there is a high 
chance that false positive reactions may occur)”
  – For epidemiological control after confirmation of 
autochthonous circulation, other acute cases of 
Zika should be confirmed through clinical-epi-
demiological criteria, except when in pregnant 
women or in  situations of neurological manifesta-
tions and death.
Congenital complications
Congenital malformations, including microcephaly, gen-
erally have complex multifactorial etiology and may 
have been caused through infection during pregnancy or 
through chromosomal disorders, exposure to environmen-
tal toxins or metabolic diseases, as shown on Table 1. The 
temporal and spatial relationship between Zika outbreaks 
and higher incidence of microcephaly in states with docu-
mented autochthonous transmission has started to indi-
cate that the existence of a causal relationship between 
these two epidemiological events is increasingly likely [30].
This relationship has become increasingly consistent, 
consequent to detection of viral RNA using the PCR 
technique for Zika in amniotic fluid, placenta, umbilical 
cord blood and cerebral tissue. The capacity of the virus 
to infect and cross the placental barrier such that it might 
then affect the nerve tissue during its formation has also 
been demonstrated [32, 33].
In Brazil, since the confirmation of the Zika outbreak, 
the incidence of microcephaly has become more than 
20 times higher than what would otherwise have been 
expected [34].
During an investigation conducted in relation to 35 
children with microcephaly, 74  % of the mothers in 
northeastern Brazil who were suspected of having had 
Zika during their pregnancies reported that they had had 
a skin rash during the first and second trimesters [35].
Retrospectively, after Brazil’s notification of cases 
to WHO, cases of microcephaly were also identified 
in French Polynesia. These cases have recently been 
reported in the literature [36].
According to guidance from the Ministry of Health, it 
is compulsory to notify cases of fetuses that are identified 
as presenting central nervous system abnormalities dur-
ing pregnancy.
In April 2016, the Centers for Diseases Control and 
Prevention (a public body in the United States for 
research, statistics, control and prevention of diseases) 
concluded that there was a causal relationship between 
prenatal infection by the Zika virus and microcephaly 
other cerebral abnormalities. This conclusion was based 
on evidence regarding Zika virus infection during pre-
natal development that was consistent with the defects 
observed, with occurrence of a rare and specific pheno-
type involving microcephaly and cerebral abnormali-
ties in fetuses or newborns with confirmed or presumed 
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congenital infection due to the Zika virus, and on data 
that strongly supported biological plausibility, including 
identification of the Zika virus in the cerebral tissue of 
the fetuses and babies affected [37].
Case definition
Notified case
“A fetus that presents at least one of the following criteria 
relating to abnormalities of the central nervous system, 
as identified through ultrasound examination [9]:
  • Presence of cerebral calcifications AND/OR
  • Presence of ventricular abnormalities AND/OR
  • At least two of the following signs of abnormalities 
of the posterior fossa: hypoplasia of the cerebellum, 
hypoplasia of the cerebellar vermis, widening of the 
posterior fossa greater than 10  mm and agenesis/
hypoplasia of the corpus callosum.”
The findings from transfontanelle ultrasound and/or 
cranial tomography include [27, 35, 38, 39]:
 – Cerebral calcifications, especially periventricular, in 
the parenchyma, thalamic areas and basal ganglion.
  – Ventriculomegaly.
  – Lissencephaly.
  – Hypoplasia of the brain stem and cerebellum
 – Abnormality of white matter attenuation.
Other ultrasound findings
 – Arthrogryposis.
  – Intrauterine growth retardation.
  – Arterial flow abnormalities in the cerebral or umbilical 
arteries.
 – Oligohydramnios or anhydramnios.
❖ Ultrasound findings can be detected from the 18th 
to 20th week of pregnancy onwards.
There may be ocular involvement, especially pigment 
abnormality and macular atrophy, and also abnormalities 
of the optic nerve [40, 41].
Complications of the central nervous system
Guillain-Barré syndrome (GBS) is an autoimmune dis-
ease characterized by acute inflammatory demyelinat-
ing polyradiculoneuropathy. Motor function is usually 
affected, starting distally and progressing proximally over 
a 4-week period. The patients present generalized weak-
ness, areflexia and varying degrees of sensory disorders 
and disorders of cranial nerve involvement. Its forms 
range from those with both motor and sensory impair-
ment to those solely with sensory impairment. The risk 
increases with age and it occurs more frequently among 
men than among women. Approximately 25  % of the 
patients require admission to an intensive care unit and 
3–5 % die. The expected annual incidence is one case per 
100,000 inhabitants [42].
Higher incidence of GBS was observed concomitantly 
with the Zika outbreaks in French Polynesia, Brazil, El 
Salvador, Colombia, Suriname and Venezuela [43].
A retrospective case–control study conducted in 
French Polynesia and published in February 2016 
reported on 42 cases of GBS that occurred during the 
outbreak of 2013–2014, with detection of IgM or IgG for 
Zika in 98 % of the patients and neutralizing antibodies 
for Zika in 100 % of the cases, compared with 56 % of the 
control group. The most common symptoms were gener-
alized muscle weakness (74 %) and facial paralysis (64 %) 
[44].
Bilateral facial paralysis was also frequently observed. 
Most of the patients (88  %) reported that, on average 
6  days before the start of neurological symptoms, they 
had a condition that was compatible with Zika virus [44].
In Venezuela, 252 cases of GBS were notified between 
January 1 and 31, 2016, with PCR positive for Zika in 
three cases, including one fatal case [45].
In Brazil between January and November 2015, 1708 
cases of GBS were notified. This total reflected very sig-
nificant increases in the numbers of cases in some states, 
especially Alagoas (516.7 %), Bahia (196.1 %), Rio Grande 
Table 1 Etiological agents and  risk factors for  microceph-
aly
Source [31]
Period and types Etiology
Congenital
Genetic Inherited genetic disorders, syndromes and 
mutations
External, chemical agents Brain injury due to teratogenic drugs, toxins 
and chemical products, including foetal 
alcohol syndrome, radiation
Metabolic diseases Diabetes
Nutritional Malnutrition (maternal malnutrition, maternal 
folate deficiency, placental insufficiency)
Vascular Hypoxic-ischemic lesions
Infectious Transplacental infections of the central nerv-
ous system STORCH infections; syphilis, 
toxoplasmosis, rubella, cytomegalovirus, 
herpes simplex virus, HIV other viruses
Post-partum
Brain vascular and non-vascular injuries
Meningitis
Encephalitis
Congenital encephalitis due to HIV
Cupper intoxication
Chronic renal failure
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do Norte (108.7  %), Piauí (108.3  %), Espirito Santo 
(78.6 %) and Rio de Janeiro (60.9 %) [46].
So far, the determinants relating to the increased inci-
dence of GBS in Brazil, Colombia, El Salvador and Suri-
name have not been definitively established, especially 
with regard to the scenario of simultaneous circulation of 
dengue, chikungunya and Zika, which are all potentially 
related to occurrences of neurological syndromes [43].
Other arbovirus diseases such as dengue, chikungunya, 
Japanese encephalitis and West Nile fever have already 
been incriminated as agents related to occurrences of GBS.
Just like other flaviviruses, the Zika virus may cause 
other neurological syndromes such as meningitis, menin-
goencephalitis and myelitis, as described in the outbreak 
in French Polynesia [44].
Laboratory abnormalities
The laboratory abnormalities are nonspecific. There have 
been reports of mild to moderate leukopenia and throm-
bocytopenia, and slight elevation of assayed concentra-
tions of serum lactic dehydrogenase, gamma glutamyl 
transferase and markers of inflammatory activity (pro-
teins, fibrinogen and ferritin) [8].
Because of the scarcity of clinical studies, what has 
been described are slight abnormalities in hematological 
parameters and even smaller changes in liver enzymes. 
In general, there are no significant abnormalities in these 
parameters.
Differential diagnosis
  • Dengue: higher fever and greater severity of myal-
gia and asthenia. There may be complications due 
to hemorrhage and hemodynamic abnormalities, 
including shock. Does not usually cause conjuncti-
vitis. Significant abnormalities in laboratory tests, 
with hemoconcentration, low platelet count and liver 
enzyme abnormalities.
  • Chikungunya: high fever as observed in dengue, but 
with the major differential that the polyarthralgia/
polyarthritis starts suddenly in a severe and debilitat-
ing manner. This may be associated with articular/
periarticular edema from the outset of the condition. 
Pruriginous skin rash may be present, with a dura-
tion that is usually shorter than in Zika. It may follow 
a course that includes mild conjunctivitis.
The main differential features of dengue, chikungunya 
and zika virus infection are shown on Table 2.
  • Parvovirus: may cause acute symmetrical arthritis or 
arthralgia, most frequently in the small joints of the 
hands and feet, and in the wrists and knees. Skin rash 
is frequently observed.
  • Rubella: generally causes low fever and coryza. Pres-
ence of skin rash initially of the face and then spread-
ing to the trunk. There may be arthritis and lymphad-
enopathy.
  • Measles: presence of fever, coughing, sore throat, 
coryza, conjunctivitis and lymphadenitis. Koplik 
spots may precede the generalized rash.
  • Rickettsiosis: characterized by occurrence of fever, 
headache, myalgia and centripetal non-pruriginous 
maculopapular exanthema. The complications have 
included hemorrhagic suffusion, hemorrhagic, res-
piratory insufficiency, kidney failure, neurological 
abnormalities and shock.
  • Malaria: periodic fever, paroxysm, kidney failure, 
jaundice, altered levels of consciousness, hepatomeg-
aly or splenomegaly and history of exposure in trans-
mission areas.
  • Leptospirosis: severe myalgia, ocular suffusion, 
rubinic jaundice, oliguria and subconjunctival hem-
orrhage. History of exposure to contaminated water.
Many recent publications have emphasized the occur-
rence of dual infections, including Zika and Dengue, 
and Zika and Chikungunya co-infections [47–51]. With 
the ongoing circulation of these viruses and the rela-
tively similar clinical presentations it is urgently needed 
the availability of molecular platforms for a more precise 
diagnosis.
Laboratory diagnosis
Types of laboratory samples available and samples 
required
The specific laboratory diagnosis is based mainly on 
detection of viral RNA from clinical specimens. In blood 
samples, detection is possible for a period of 1–5  days 
after the start of symptoms [52, 53]. Negative results do 
not rule out the diagnosis, because the sensitivity of RT-
PCR is estimated to be 40 %.
Because of the greater persistence of the virus in urine, 
patients seen after the fifth day of the disease should 
undergo RT-PCR on urine. This analysis is indicated up 
to the 15th day after the start of symptoms [52, 53].
It is generally considered that serological tests are able 
to detect IgM from the 4th day and IgG from the 12th day.
Serological tests for Zika in populations with simulta-
neous or previous circulation of other flaviviruses may be 
imprecise because of the risk of cross-reactions, thereby 
leading to false positive results. For this reason, positive 
results should be analyzed cautiously since they might 
represent previous exposure to other flaviviruses (such as 
the dengue virus) or vaccination in the past against yel-
low fever or Japanese encephalitis [52, 53].
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Negative serological results (non-reactive IgM and IgG) 
suggest that infection did not occur, if the test was done 
between 2 and 12 weeks after the exposure [53]. Figure 1 
shows the summary of the recommendations for labora-
torial diagnosis of zika virus infection. Tables 3, 4 and 5 
show the recommendations for collecting, storing, con-
serving and transporting serological samples, virus isola-
tion and molecular diagnosis in suspected cases of Zika.
Brazilian Ministry of Health’s guidelines determines 
to collect samples from the first cases in an area with-
out laboratory confirmation of acute Zika virus disease, 
from 100 % (all) of the pregnant women with suspected 
acute Zika virus disease, from 100  % (all) of the deaths 
suspected to be due to acute Zika virus disease and from 
100 % (all) of the patients hospitalized in sentinel units, 
with neurological manifestations and with suspected pre-
vious viral infection (Zika, dengue and chikungunya).
Interpretation of the results
  – A positive molecular test confirms the diagnosis of 
Zika.
  – A negative molecular test does not rule out the possi-
bility of Zika.
  – A reactive serological test for Zika may be due to acute 
infection by the virus, a cross-reaction with other flavi-
viruses or a result from yellow fever vaccination.
Case management
Management of acute zika syndrome
There is no specific antiviral treatment.
The treatment consists of rest, oral hydration and use 
of medications for symptoms.
Analgesics and antipyretics such as dipyrone and 
paracetamol.
Antihistamine medications to control itching.
Non-steroidal anti-inflammatory drugs (NSAIDs) 
should not be used until the diagnosis of dengue has 
been ruled out [54]. Avoid their use in pregnant women 
beyond the 32nd week of gestation because of the risk of 
early closure of the arterial duct.
Avoid use of aspirin in children under the age of 
12 years because of the risk of Reye syndrome.
It is important to evaluate differential diagnoses, espe-
cially in relation to dengue, because of the greater risk of 
evolution to severe cases. Treat all cases as dengue until 
this diagnosis has been ruled out.
Management of pregnant women
Currently, only limited data on pregnant women infected 
with the Zika virus are available. The data suggest that 
pregnant women may become infected with the Zika 
virus in any trimester. However, the incidence of Zika 
virus infection among pregnant women is unknown. 
There is no evidence to suggest that pregnant women are 
more susceptible to Zika or that they present disease of 
greater severity than do other individuals [55].
Regarding transmission of the Zika virus, there is evi-
dence of virus transmission from the mother to the fetus 
during pregnancy and also close to the time of deliv-
ery.  Since no vaccines or prophylactic medications for 
avoiding Zika virus infection exist, the Brazilian Society 
of Infectology (SBI) recommends (in agreement with the 
Centers for Disease Control and Prevention, CDC) that 
women in any trimester of pregnancy should consider 
Table 2 Differential diagnosis of dengue, zika and chikungunya in symptomatic cases
Adapted from a panel of specialists of the Brazilian Society of Infectology (SBI), as modified from the source: Health Surveillance Secretariat of the Ministry of Health 
“Surveillance and response protocol for occurences of microcephaly related to zika virus infection” Brasilia, Federal District, December 2015
Signs/symptoms Dengue Zika Chikungunya
Fever (duration) Higher than 38 °C (4–7 days) No fever or low fever < 38.5 °C 
(1–2 days)
High fever > 38 °C (2–3 days)
Skin rash (frequency) Moderately elevated Elevated Moderately elevated
Myalgia (frequency) +++/+++ ++/+++ ++/+++
Arthralgia (frequency) Rare Variable, in wrists and hands, with 
complete regression
Frequent and in multiple joints
Severity of arthralgia Mild Mild/moderate Moderate/severe
Articular/periarticular edema (fre-
quency)
Rare Mild severity Frequent and moderate to severe
Non-purulent conjunctivitis Rare 50–90 % of cases 30 %
Headache (frequency and intensity) Frequent and high intensity Frequent and moderate intensity Frequent and moderate intensity
Pruritus Mild Moderate to severe Mild
Lymphadenopathy (frequency) Rare Moderate Moderate
Neurological complications Encephalitis (rare) Guillain-Barré syndrome, encephalitis 
(rare)
Guillain-Barré syndrome, encephalitis 
(predominantly in neonates)
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postponing journeys to areas with transmission of this 
virus. If a pregnant woman lives in or travels to an area 
with transmission of the Zika virus, she should protect 
herself to avoid mosquito bites.
Pregnant women who present symptoms compatible 
with Zika (including fever, skin eruptions, joint pains and 
red eyes) need to be given priority for laboratory investi-
gation in order to diagnose Zika virus infection.
Routine prenatal use of serological tests for Zika among 
pregnant women living in areas with the Zika epidemic is 
not recommended by the Brazilian Ministry of Health.
The centers for disease control and prevention (CDC) 
recommends
  – If a laboratory test is positive for Zika or inconclusive, 
use of serial ultrasound examinations should be con-
sidered.
  – For pregnant women whose fetus has a confirmed 
diagnosis of microcephaly, the possibility of amniocen-
tesis should be evaluated from the 15th week of preg-
nancy onwards.
  – Pregnant women in a transmission area should 
undergo serological tests for Zika at the start of their 
prenatal care.
 – Serological tests should be offered to women in areas 
without autochthonous transmission if they have a his-
tory of travel to an area with known Zika virus trans-
mission and are asymptomatic (i.e. without reports of 
sickness consistent with Zika). These tests should be 
performed 2–12 weeks after the trip.
The Brazilian Federation of Gynecology and Obstetrics 
Associations (FEBRASGO) recommends the following in 
cases of pregnant women with clinical manifestations of 
Zika:
  – Ultrasound examination should be scheduled every 
month until delivery [56]
The American Society of Gynecology and Obstetrics rec-
ommends the following in cases of pregnant women with 
serological findings that are positive for Zika or inconclu-
sive, and/or who show symptoms of Zika infection:
 – If, at the time of the symptoms or the serological tests, 
the pregnant woman has not reached her 20th week 
of pregnancy, an ultrasound examination should be 
scheduled every 3 to 4 weeks, starting at the 18th week.
 – If, at the time of the symptoms or the serological tests, 
the pregnant woman is already beyond her 20th week 
of pregnancy, an ultrasound examination should be 
scheduled every 3–4 weeks, from the time of diagnosis 
onwards.
The summary of current reccomendations for diagnos-
tic of zika virus infection in pregnant women in shown 
on Fig.  2. Figure  3 illustrates a diagnostic algorithm for 
different arboviral diseases in pregnant women.
Management of microcephaly and congenital 
malformations
It is very important to record the gestational age at birth 
when assessing the size of the skull in newborns [57].
The INTERGROWTH-21st allows measuring the 
head circumference, at birth, across many different 
populations and it has been obtained through rigorous 
TEST
SPECIFIC TESTS
ZIKA
Isolation of virus: up to 5th day*
IgM is positive from 4th-7th day to 2-
12 weeks
IgG is positive after 12th day
RT-PCR on blood is positive up to 4th-5th day
RT-PCR on urine is positive up to 15th day
Fig. 1 Summary of the recommendations for specifically diagnosing Zika
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methodology and standardised procedures. This is very 
important in the context of the Zika virus outbreak, as 
reliable information on the head circumference of new-
borns according to their gestational age is required so as 
to screen for microcephaly [57].
Criteria for notification of newborn with microcephaly 
according to the Ministry of Health’s recommendations 
[9]:
 – Newborns with gestational age of less than 37  weeks 
that present a head circumference measurement of less 
than −2 standard deviations for the gestational age and 
sex, as described in the InterGrowth table.
 – Newborns with gestational age of 37 weeks or more that 
present a head circumference measurement of less than 
or equal to 31.5 cm for girls and 31.9 for boys, which is 
equivalent to less than −2 standard deviations for the 
neonate’s age and sex, as described in the WHO table.
According to WHO and the international literature, 
microcephaly is defined as a head circumference of less 
than minus two standard deviations of the reference for 
the sex, age or length of gestation. The head circumfer-
ence must be measured using standardized technique 
and equipment between 24 h and 6 days 23 h after birth 
(i.e. within the 1st week of life).
Severe microcephaly is defined as a head circumference 
of less than −3 standard deviations, i.e. more than three 
standard deviations below the mean for the gestational 
age and sex.
According to WHO, newborns with microcephaly who 
present structural abnormalities of the brain, as diag-
nosed through imaging examinations or observed neu-
rological or developmental abnormalities, should be 
classified as having “microcephaly with brain abnormal-
ity”. All neonates with microcephaly should receive regular 
evaluations and follow-up during their childhood, includ-
ing: head growth, the mother’s and family’s histories of 
pregnancies, evaluation of development and physical and 
neurological examinations, including evaluation of hearing 
and eyesight, to identify any problems. To detect structural 
abnormalities of the brain, WHO recommends that trans-
fontanelle ultrasound examinations should be performed 
when the size of the fontanelle is sufficient for this proce-
dure. For neonates who present severe microcephaly (−3 
standard deviations), cerebral computed tomography or 
magnetic resonance imaging should be performed.
Microcephaly may be accompanied by epilepsy, cer-
ebral palsy, delayed cognitive, motor and speech develop-
ment and hearing and eyesight problems.
There is no specific treatment for microcephaly. Since 
each child develops complications that differ in type and 
severity, which may include respiratory, neurological and 
motor problems, the follow-up by different specialists 
will depend on which functions have been compromised.
The summary of current reccomendations for diagnos-
tic of Zika virus infection in newborns in shown on Fig. 4.
Management of guillain-barré syndrome
Because of the autoimmune nature of Guillain-Barré 
syndrome, its treatment in the acute phase consists of 
immunotherapy, such as plasmapheresis or application of 
human immunoglobulin. When corticosteroids are used 
separately, this does not accelerate the recovery or alter 
the long-term result [58].
The aim of plasmapheresis is to remove the antibod-
ies from the bloodstream and replace them with artificial 
plasma, usually albumin. The result is better when the 
procedure is started within the first 7–14 days after the 
onset of neurological symptoms [58].
Human immunoglobulin accelerates recovery, as 
observed with plasmapheresis. It is relatively simple to 
administer. The best results are obtained when it is started 
within the first 2 weeks after the symptoms begin [58].
Endovenous dose of human immunoglobulin: 400 mg/
kg of body weight per day, for a period of 5 days.
GROUP
Pregant women 
with possible 
Zika infection 
during 
pregnancy
LABORATORY TEST– SPECIFIC FOR ZIKA
RT-PCR up to 5th day - blood
RT-PCR after 5th day – urine
Serological tests – 3rd to 5th day after 
start of symptoms
Serological tests – 2 to 4 weeks after first 
serological tests
LABORATORY TEST – OTHER 
INFECTIOUS AGENTS
Serological tests or 
RT-PCR for dengue, 
chikungunya or 
STORCH
Fig. 2 Summary of the recommendations for specifically diagnosing Zika in pregnant women
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Diagnosis of Guillain-Barré syndrome [42]:
 – Clinical history and neurological examination.
  – Collection of cerebrospinal fluid, in which it is 
expected to find an increased protein concentration, to 
the detriment of increased cellularity.
  – Patients with suspected syndrome and cellularity 
greater than 50  cells/mm3 should be investigated for 
other etiologies or for concomitant HIV infection.
  – The cerebrospinal fluid may be normal in the hypera-
cute phase (first week).
  – Electroneuromyography is the examination that con-
firms the diagnosis, but it may be normal in the 1st week.
  – Imaging examinations are generally normal.
Public health control measures
Vector control measures:
  • Basic sanitation.
  • Elimination of vector foci in homes and common 
areas.
Pregnant women with 
symptoms compable with 
Dengue, Chikungunya or Zika  
Acute phase  
Convalescent 
phase   
RT-PCR for 
Zika in blood, 
urine or 
saliva 
Dengue 
serology 
reacvity 
confirms 
Dengue 
If Posive 
Zika  is 
confirmed 
If negave
Look out for 
Dengue or 
Chikungunya 
Cannot 
definitely rule 
out  Zika  
Chikungunya 
serology 
reacvity 
confirms 
Chikungunya  
RT-PCR for 
Dengue in 
blood or NS1  
If Posive 
Dengue is 
confirmed 
If Negave 
Look out for 
Zika or 
Chikungunya 
if performed 
on first 5 
days of 
symptoms 
onset
Zika serology 
may cross-
react with 
Dengue. Some 
paents may 
have an IgG 
booster 
reacon  for 
Zika without 
IgM 
seroreacvity 
Zika virus PRNT cannot 
definitely confirm or rule 
out Zika acute infecon in 
Brazil where co-circulaon 
of Dengue and Zika are 
widespread, and/or 
extensive vaccinaon for YF 
occurs. 
Not performed in any 
commercial laboratory 
All pregnant women should have STORCH screening 
serologies performed during antenatal visits
RT-PCR for 
Chikungunya  
in blood or 
urine 
If Posive 
Chikungunya 
is confirmed 
If Negave 
Look out for 
Zika or 
Dengue if 
performed on 
first 6 days of 
symptoms 
onset.  
Fig. 3 Diagnostic algorithm for different arboviral diseases in pregnant women
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  • Reduction of garbage accumulation through urban 
cleansing campaigns in areas where garbage col-
lection is irregular, and through increasing the fre-
quency of garbage collection.
  • Implementation of vector control through physical, 
biological and chemical methods, with involvement 
of families and communities.
  • In areas with autochthonous transmission or imported 
cases of transmission of dengue, chikungunya and/or 
Zika, blockage of cases through using pesticides tar-
geting adult vectors, primarily through spraying, is 
recommended, in addition to use of larvicides.
  • Fieldwork done by endemic disease agents for con-
trolling both the larvae and the adult mosquitos 
needs to be monitored and controlled.
  • Mosquito control is the only measure that can inter-
rupt the transmission of arbovirus diseases such as 
Zika, dengue and chikungunya.
Prevention and personal protection
In order not to infect other people, infected individuals 
should protect themselves from bites by Aedes during the 
1st week (viremic phase).
There is still no vaccine for prevention of infection by 
the Zika virus.
Steps for preventing mosquito bites
  • Use long-sleeved shirts and long trousers/pants.
  • Stay in enclosed places with air conditioning or 
places with windows and doors that have screens to 
prevent the entry of mosquitos.
  • Sleep under mosquito nets.
  • Use registered insect repellents. When these are used 
as instructed, they are safe and effective, even during 
pregnancy or breastfeeding.
 – Always follow the guidance of instruction leaflets.
  – Avoid using products that combine repellent and 
sun protection in the same formulation. The sun 
protection factor decreases by one-third when used 
together with insect repellent.
 – If sun protection is used, apply it before applying 
the repellent.
  • For children
 – Do not use repellent on children under the age of 
2 months.
  – Dress children in clothes that cover their arms and 
legs.
  – Cover cots and pushchairs with mosquito nets.
 – Do not apply repellent to children’s hands.
  • Clothes impregnated with permethrin can be used.
  – Do not use products containing permethrin directly 
on the skin.
In Brazil, the National Health Surveillance Agency 
(ANVISA) only recommends use of repellents for chil-
dren over the age of 6 months. The Centers for Disease 
Control and Prevention (CDC) recommends their use 
from the age of 2 months, except for lemon eucalyptus, 
which should only be used from the age of 3 years.
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GROUP
Newborns with central 
nervous system 
involvement probably 
related to Zika virus 
infection during 
gestation, seen on 
ultrasound or CT scan 
(microcephaly, 
calcifications etc)
Serological tests – microcephaly
Serological tests – 2 to 4 weeks after 
first serological tests
Serological tests and RT-PCR on cord 
blood, placenta and cerebrospinal fluid 
and at birth
Serological tests 
on mother: 
dengue, 
chikungunya or 
STORCH
Fig. 4 Summary of the recommendations for specifically diagnosing Zika among newborns
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